Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects

Ceuppens, Jan L.; Bullens, Dominique; Kleinjans, H. A. J.; Werf, J. van der

doi:10.1111/j.1365-2222.2009.03379.x

Cited by 40 publications

(40 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in our study, the suppressive effect of the therapy on basophil activation at the end of treatment and at the peak of the grass pollen season after treatment further supports the powerful immunogenicity of allergoids. Some studies have shown that sera containing therapy-induced allergen-specific IgG can suppress basophil activation [20,26,27,28]. In this study, we reported a pronounced increase of allergen-specific IgG4 after immunotherapy.…”

Section: Discussionsupporting

confidence: 64%

“…However, there are several studies showing the increment of specific IgG antibodies by allergoid immunotherapy [22,26,27]. As shown in our study, the suppressive effect of the therapy on basophil activation at the end of treatment and at the peak of the grass pollen season after treatment further supports the powerful immunogenicity of allergoids.…”

Section: Discussionsupporting

confidence: 59%

See 1 more Smart Citation

Short-Term Preseasonal Immunotherapy: Is Early Clinical Efficacy Related to the Basophil Response?

Özdemir¹,

Sin²,

Güloğlu³

et al. 2014

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: An aluminum hydroxide-adsorbed depot allergoid preparation of six-grass pollen allergens has been developed for short-term preseasonal immunotherapy in pollinosis. However, only limited knowledge exists about its immunological and clinical effects. The aim of this study was to evaluate the basophil response, which can explain early clinical findings of short-term preseasonal allergoid immunotherapy in allergic rhinitis. Methods: In a double-blind, placebo-controlled study, 31 patients allergic to grass pollens received one course of short-term preseasonal allergoid immunotherapy or placebo. Immunogenicity was assessed by the levels of specific IgG4, IgE antibodies and an allergen-induced CD203c basophil activation test. The primary clinical end point was the combined symptom and medication score/average combined score (ACS). Results: There was a 52.9% difference in ACS between the treatment and placebo groups in favor of immunotherapy (p = 0.01). Active treatment induced Phleum pratense-specific IgG4 and IgE antibodies (p < 0.05). A decrease in allergen-induced basophil activation at submaximal allergen concentrations was demonstrated at the end of immunotherapy and at the peak of the grass pollen season after immunotherapy. Conclusions: This study shows that grass pollen-allergic patients treated with one course of short-term preseasonal allergoid immunotherapy exhibit a decrease in allergen-induced basophil activation, an increase in allergen-specific IgG4 antibodies and early clinical improvement.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussionsupporting

confidence: 59%

Short-Term Preseasonal Immunotherapy: Is Early Clinical Efficacy Related to the Basophil Response?

Özdemir¹,

Sin²,

Güloğlu³

et al. 2014

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Some authors describe reduction in basophil activation following AIT possibly due to serological factors [Ceuppens et al 2009;Aasbjerg et al 2014;Ozdemira et al 2014;Schmid et al 2014]. Van Overtvelt and Gomez failed to demonstrate the effects of AIT on basophil activation following AIT [Van Overtvelt et al 2011;Gomez et al 2015].…”

Section: Cellular Changesmentioning

confidence: 99%

Applications and mechanisms of immunotherapy in allergic rhinitis and asthma

Kappen

Durham

Veen

et al. 2016

Ther Adv Respir Dis

View full text Add to dashboard Cite

Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such as mast cells, eosinophils and basophils in target organs. Furthermore, AIT down-regulates type 2 innate lymphoid cells and allergen-specific type 2 T-helper (Th2) cells. The immunologic tolerant state following AIT is associated with the induction of distinct phenotypes of regulatory T-cells (T-regs) including interleukin (IL)-10-, IL-35-and transforming growth factor (TGF)-β-producing T-regs and FoxP3 + T-regs. B-cell responses, including the induction of IL-10 + regulatory B-cells (B-regs) and the production of IgG4-associated blocking antibodies are also induced following successful AIT. These events are associated with the suppression of antigen-specific Th2 responses and delayed immune deviation in favour of Th1 type responses. Insight into the mechanisms of AIT has allowed identification of novel biomarkers with potential to predict the clinical response to AIT and also novel therapeutic strategies for more effective and safer AIT.

show abstract

“…Studies have shown that clinical efficacy is retained using modified allergen extracts at higher doses and that modified preparations are considered safer than nonmodified allergen extracts [1,2,3,4]. …”

Section: Introductionmentioning

confidence: 99%

Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation

Buczyłko

Werf

Boot

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Early pollen flight and new allergens prolonging the pollen season means that the time for up-dosing of allergen-specific subcutaneous immunotherapy (SCIT) outside the pollen season becomes shorter. Hence, for patients who wish or need to be up-dosed faster, an accelerated induction regimen would provide a useful treatment option. Methods: An accelerated up-dosing regimen (0.1-0.3-0.5 mL at weekly intervals) was compared to conventional up-dosing (0.05-0.1-0.2-0.3-0.4-0.5 mL at weekly intervals) using an allergoid birch pollen SCIT preparation. After up-dosing, the maintenance dose (0.5 mL) was given 3 times at biweekly intervals. The multicenter study was performed according to an open randomized, parallel-group design. Results: A total of 123 birch pollen-allergic patients (81 adults and 42 adolescents) presenting with rhinitis or rhinoconjunctivitis with or without mild asthma (FEV₁ >70%) were randomized to either the conventional registered up-dosing or an accelerated regimen. In total, 96.7 and 98.4% successfully reached the maintenance dose for the conventional and accelerated regimen, respectively, without relevant differences between adults and adolescents. Both regimens were safe and well tolerated. Furthermore, significant increases (similar in size) in specific IgG and IgG₄ after 3 months of treatment were observed in both groups, independent of age. Conclusion: The accelerated SCIT regimen was revealed to be as safe as the conventional regimen, and the immunological effects of both regimens are similar. Accordingly, the accelerated regimen may be used to up-dose patients of adult as well adolescent age within 2 weeks.

show abstract

Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects

Abstract: Immunotherapy with a modified slow-release birch pollen extract, administered in a single-strength preparation with a rapid dose increase, is safe and efficacious. IgG and IgG4 antibodies against native Bet v 1 are induced, which block basophil activation.

Cited by 40 publications

References 25 publications

Short-Term Preseasonal Immunotherapy: Is Early Clinical Efficacy Related to the Basophil Response?

Short-Term Preseasonal Immunotherapy: Is Early Clinical Efficacy Related to the Basophil Response?

Applications and mechanisms of immunotherapy in allergic rhinitis and asthma

Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation

Contact Info

Product

Resources

About